Skip to main content

Advertisement

Table 1 Demographic characteristics of patients who received MMF treatment for six months or longer

From: Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study

Characteristic Value
Number of Patients n = 86
Current age, median (range), y 53 (15–84)
Female sex, No. (%) 77 (90%)
NMO diagnosis, No. (%) 64 (74%)
NMOSD diagnosis, No. (%) 22 (26%)
Aquaporin-4 antibody positivity, No. (%) 74 (86%)
Age at onset, median (range), y 43 (6–68)
Overall disease duration, median (range), mo 71 (7–535)
Disease duration before receiving MMF, median (range), mo 71 (6–444)
Attack number before receiving MMF, median (range) 5 (1–33)
Duration of MMF treatment, median (range), mo 20 (6–89)
Abnormal autoantibodiesa, n (%) 39 (45%)
Coexisting with systemic autoimmune diseases 29 (34%)
Concurrent use of prednisone, n (%) 65 (76%)
treatment-naïve patients, n (%) 21 (24%)
Previous immunosuppressive agents:
 Corticosteroidsb, n (%) 33 (38%)
 Azathioprine, n (%) 15 (17%)
 Cyclophosphamide, n (%) 4 (5%)
 Rituximab, n (%) 2 (2%)
 Tacrolimus (FK506) 1 (1%)
 Methotrexate 1 (1%)
Previous immunomodulatory therapies:
 β-interferons, n (%) 6 (7%)
 hydroxychloroquine sulfate, n (%) 2 (2%)
 Mitoxantrones, n (%) 1 (1%)
  1. aAutoantibodies refers to rheumatoid factors, antinuclear antibodies, anti–double-stranded DNA antibodies, ribose nuclear proteins, anti-SM antibodies, anti-SSA and anti-SSB antibodies, TPO and TG antibodies
  2. bCorticosteroids refers to continuously taking oral prednisone or methylprednisolone for more than 3 months